A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation
dc.contributor.author | Fellenor, J | |
dc.contributor.author | Britten, N | |
dc.contributor.author | Courtenay, M | |
dc.contributor.author | Payne, RA | |
dc.contributor.author | Valderas, J | |
dc.contributor.author | Denholm, R | |
dc.contributor.author | Duncan, P | |
dc.contributor.author | McCahon, D | |
dc.contributor.author | Tatnell, L | |
dc.contributor.author | Fitzgerald, R | |
dc.contributor.author | Warmoth, K | |
dc.contributor.author | Gillespie, D | |
dc.contributor.author | Turner, K | |
dc.contributor.author | Watson, M | |
dc.date.accessioned | 2021-01-22T16:13:52Z | |
dc.date.issued | 2021-01-13 | |
dc.description.abstract | Background Up to 50% of medicines are not used as intended, resulting in poor health and economic outcomes. Medicines optimisation is ‘a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines’. The purpose of this exercise was to co-produce a prioritised research agenda for medicines optimisation using a multi-stakeholder (patient, researcher, public and health professionals) approach. Methods A three-stage, multiple method process was used including: generation of preliminary research questions (Stage 1) using a modified Nominal Group Technique; electronic consultation and ranking with a wider multi-stakeholder group (Stage 2); a face-to-face, one-day consensus meeting involving representatives from all stakeholder groups (Stage 3). Results In total, 92 research questions were identified during Stages 1 and 2 and ranked in order of priority during stage 3. Questions were categorised into four areas: ‘Patient Concerns’ [e.g. is there a shared decision (with patients) about using each medicine?], ‘Polypharmacy’ [e.g. how to design health services to cope with the challenge of multiple medicines use?], ‘Non-Medical Prescribing’ [e.g. how can the contribution of non-medical prescribers be optimised in primary care?], and ‘Deprescribing’ [e.g. what support is needed by prescribers to deprescribe?]. A significant number of the 92 questions were generated by Patient and Public Involvement representatives, which demonstrates the importance of including this stakeholder group when identifying research priorities. Conclusions A wide range of research questions was generated reflecting concerns which affect patients, practitioners, the health service, as well the ethical and philosophical aspects of the prescribing and deprescribing of medicines. These questions should be used to set future research agendas and funding commissions. | en_GB |
dc.description.sponsorship | GW4 | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.identifier.citation | Vol. 21, article 64 | en_GB |
dc.identifier.doi | 10.1186/s12913-021-06056-5 | |
dc.identifier.grantnumber | GW4-IF10–001 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/124473 | |
dc.language.iso | en | en_GB |
dc.publisher | BMC | en_GB |
dc.rights | © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. | en_GB |
dc.subject | Medicines optimisation | en_GB |
dc.subject | Polypharmacy | en_GB |
dc.subject | Deprescribing | en_GB |
dc.subject | Patient concerns | en_GB |
dc.subject | Non-medical prescribing | en_GB |
dc.subject | Nominal group technique | en_GB |
dc.title | A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-01-22T16:13:52Z | |
exeter.article-number | 64 | en_GB |
dc.description | This is the final version. Available on open access from BMC via the DOI in this record | en_GB |
dc.description | Availability of data and materials: The datasets used and/or analysed during the current exercise are available from the corresponding author on request. | en_GB |
dc.identifier.eissn | 1472-6963 | |
dc.identifier.journal | BMC Health Services Research | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-01-02 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-01-13 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-01-22T16:11:16Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2021-01-22T16:14:01Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.